

GLAXOSMITHKLINE PLC
Form 6-K
September 26, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 26 September 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

- c) Price(s) and volume(s) Price(s) Volume(s)
£16.49 14,376.963 notional Ordinary Shares.
- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price
- f) Date of the transaction 2016-09-23
- g) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
- b) Position/status President, Global Pharmaceuticals
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Hussain will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.49 17,971.204 notional Ordinary Shares
d) Aggregated information	n/a (single transaction)
e) Date of the transaction	2016-09-23
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
c) Price(s) and	Price(s) Volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

volume(s)	£16.49	14,376.963 notional Ordinary Shares
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2016-09-23	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£16.49	14,376.963 notional Ordinary Shares
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2016-09-23	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Dr P J T Vallance
b) Position/status President, Pharmaceuticals Research & Development
c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
- c) Price(s) and volume(s) Price(s) Volume(s)
£16.49 17,971.204 notional Ordinary Shares
Aggregated information n/a (single transaction)
- d) Aggregated volume Price
- e) Date of the transaction 2016-09-23
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: September 26, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc